India, Feb. 2 -- The Government of India has issued a release:
Key Takeaways
Introduction
The Union Budget 2026-27 marks a decisive shift in India's approach to pharmaceuticals by placing biopharma and biologic medicines at the centre of its healthcare and manufacturing strategy. This aligns with the Government of India's vision of transforming India into a leading global biopharma industry and capturing 5% of the global biopharmaceutical market share.[1] [2]
Acknowledging the growing burden of non-communicable diseases and the increasing global reliance on biologics and biosimilars, the Budget positions biopharma as a high-value, future-facing segment critical for both public health and economic growth.
Biopharma involves production, ...